Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials by Lourenco T et al.
RESEARCH
Minimally invasive treatments for benign prostatic
enlargement: systematic review of randomised controlled
trials
Tania Lourenco, research fellow,1 Robert Pickard, senior clinical lecturer,2 Luke Vale, professor of health
technology assessment,1,3 Adrian Grant, professor of health services research,1 Cynthia Fraser, information
officer,1 Graeme MacLennan, statistician,1 James N’Dow, professor of urology,4 and the Benign Prostatic
Enlargement team
ABSTRACT
Objective To compare the effectiveness and risk profile of
minimally invasive interventions against the current
standard of transurethral resection of the prostate.
Design Systematic review and meta-analysis of
randomised controlled trials.
Data sources Electronic and paper records up to March
2006.
ReviewmethodsWe searched for all relevant randomised
controlled trials. Two reviewers independently extracted
data and assessed quality. Meta-analyses of prespecified
outcomes were performed with fixed and random effects
models and reported using relative risks or weighted
mean difference.
Results 3794 abstracts were identified; 22 randomised
controlled trialsmet the inclusion criteria. These provided
data on 2434 participants. The studies evaluated were of
moderate to poor quality with small sample sizes.
Minimally invasive interventions were less effective than
transurethral resection of the prostate in terms of
improvement in symptom scores and increase in urine
flow rate, with most comparisons showing significance
despite wide confidence intervals. Rates of reoperation
were significantly higher for minimally invasive
treatments. The risk profile of minimally invasive
interventions was better than that of transurethral
resection, with fewer adverse events. The results,
however, showed significant heterogeneity.
ConclusionWhich minimally invasive intervention is the
most promising remains unclear. Their place in the
management of benign prostate enlargement will
continue to remain controversial until well designed and
well reported randomised controlled trials following
CONSORT guidelines prove they are superior and more
cost effective than drug treatment, or that strategies of
sequential surgical treatments are preferred by patients
and are more cost effective than the more invasive but
more effective tissue ablative interventions such as
transurethral resection.
INTRODUCTION
Benign prostatic enlargement is the commonest cause
of lower urinary tract symptoms such as frequency of
urination and slow stream, which are highly prevalent
among older men. Endoscopic removal of the inner
part of the gland by transurethral resection of the
prostate has long been considered as themost effective
treatment, with about 20 000 procedures carried out in
2007 in the United Kingdom. This procedure has
knowndisadvantages, includingblood loss andphysio-
logical stress, which affect recovery in some men,
together with the need for high levels of technical skill
and a three to five day stay in hospital.1 These factors
have encouraged the development of alternative
treatments, including drugs, minimally invasive surgi-
cal techniques, and different forms of endoscopic
prostatectomy, with the intention of achieving the
samedegreeof improvementof symptomsbutwith less
morbidity and lower cost. Minimally invasive techni-
ques aim to reduce prostate volume by delayed tissue
necrosis using relatively low levels of thermal energy
and thus reducing the risk of morbidity related to
treatment.
We carried out a systematic review to summarise
evidence of benefit and risk for seven promising
minimally invasive technologies compared with trans-
urethral resection using data from randomised con-
trolled trials.
METHODS
Search strategy
To identify published and unpublished reports of
relevant randomised controlled trials we carried out
highly sensitive electronic searches of relevant data-
bases and recent conference proceedings (Medline
(1966-September, week 3, 2006), Embase (1980-2006,
week 38), Medline In-Process (27 September 2006),
Biosis (1985-22 September 2006), Science Citation
Index (1981-23 September 2006), ISI Proceedings
(1990-18 March 2006), Cochrane Controlled Trials
Register and Cochrane Database of Systematic
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Reviews (Cochrane Library, Issue 1, 2006), Database
of Abstracts of Reviews of Effectiveness (March 2006),
HTA Database (March 2006), National Research
Register (Issue 1, 2006), Clinical Trials (March 2006),
Current Controlled Trials (March 2006), and proceed-
ings of the European Association of Urology, Amer-
icanUrologicalAssociationand theBritishAssociation
of Urological Surgeons). We defined minimally
invasive treatments as those that reduce prostate
volume by delayed tissue necrosis using low energy
heating devices. Searcheswere not restrictedby year of
publication or language and included abstracts from
conference proceedings. Reference lists of all included
studies were scanned to identify additional potentially
relevant studies. Full details of the search strategies
used are available from the authors on request. Two
reviewers (fromTL andAngelaCoutts or SusanWong
orGhulamNabi) independently screened the titles and
abstracts of identified papers, and full text copies of all
potentially relevant studies were obtained.
Selection and study characteristics
We included randomised controlled trials if they
comparedminimally invasive interventions for benign
prostatic enlargement with transurethral resection of
the prostate. We excluded trials reporting on men
without a clinical diagnosis of benign prostatic
enlargement and comparisons against conservative
management. The table shows the interventions
considered (table A on bmj.com provides full descrip-
tions of the treatments). Theprimaryoutcomemeasure
was change in symptom score 12months after surgery,
measured by the international prostate symptom score
or the American Urological Association symptom
index—these were considered equivalent and we
therefore combined trials using these instruments.
The international prostate symptom score/American
Urological Association symptom questionnaire asks
men to rate four voiding symptoms (poor stream,
intermittent flow, straining, incomplete emptying) and
three storage symptoms (frequency, nocturia, urgency)
ona scale from0 (notpresent) to5 (severe) togivea total
score ranging from 0 to 35, with severity of symptoms
defined as mild (0-7), moderate (8-19), or severe (20-
35).
Secondary outcomeswere improvement in quality of
life and increase in peak urine flow rate (for effective-
ness); blood transfusion, urinary incontinence, urinary
retention, urethral stricture, urinary tract infection,
retrograde (loss of) ejaculation, erectile dysfunction
(for morbidity); and duration of operation, length of
hospital stay, and need for reoperation (for descriptors
of care). We considered all reports of prespecified
complications regardless of their timing. As separate
reporting of stenosis of the bladder neck and urethral
stricture was inconsistent we combined these complica-
tions.
Validity assessment and data abstraction
Two reviewers (as above), independently assessed the
quality of methods of the full text studies using an
assessment tool drawingon the schema suggestedby the
National Health Service Centre for Reviews and
Dissemination,2 Verhagen et al,3 Downs and Black,4
and the generic appraisal tool for epidemiology.
Judgments on quality were based on the qualitative
assessment of the number and type of criteria met by
individual studies.
The two reviewers recorded details of methods,
interventions, participants’ characteristics, and out-
comes on a data extraction form. Any differences that
could not be resolved through discussion were decided
by an arbiter. For trials with multiple publications we
included only the most complete report for each
outcome.
Quantitative data synthesis
For meta-analysis we combined dichotomous outcome
data using the Mantel-Haenszel relative risk method.
For continuous outcomes we used inverse variance
weighted mean differences and 95% confidence inter-
vals. We intended to report results using a fixed effects
model throughout, but we had to use a random effects
model for symptom score and peak urine flow rate
because of statistical heterogeneity, explored by χ2 tests
and I2 statistics. We used the standard Cochrane
software RevMan 4.2.8 for meta-analyses.
RESULTS
The initial search generated 3794 reports, of which 621
were selected for full assessment (see fig A on bmj.com).
Fifty four reports describing 22 trials met the eligibility
criteria (table).
We classed the 22 full text randomised controlled
trialsw1-w22 as beingmoderate or poor quality (see tableB
onbmj.com).Only eight studies (36%)w6 w11 w12 w14-w16 w18
w21 explicitly stated that an intention to treat analysiswas
performed and in seven of these, this was compromised
by failure to include the total number of participants in
each arm at subsequent follow-up assessments.w6 w12 w14-
w16 w18 w21 A further trial was compromised by allowing
substitution of patients who failed to complete their
assigned treatment or did not attend for follow-up.w1
None of the trials provided information on whether the
interventions were undertaken by someone experi-
enced in performing the procedure, and some studies
were unclear about howmany patients were assessed at
each follow-up.Trial setting andbaseline characteristics
of the patients, such as disease severity measured by
international prostate symptom score, varied across the
included trials.Typesof laser anddeliverymodeof laser
coagulation also varied (see table C on bmj.com). The
eligible trials included 24 relevant comparisons invol-
ving 2434 participants. We could not assess differences
in outcome between transurethral resection and high
intensity focused ultrasound,water thermotherapy, and
transurethral ethanol ablation of prostate because of the
lack of data.
Quantitative data synthesis
Symptom scores—Results from studies reporting change
in symptom score from baseline to 12 months showed
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significant heterogeneity so we carried out random
effect meta-analyses (fig 1). There was generally less
improvement in symptom score for patients who
underwent transurethral microwave treatment, transur-
ethral needle ablation, and laser coagulation than
transurethral resection of the prostate (table D on
bmj.com): weighted mean difference 2.26, 95% con-
fidence interval −0.38 to 4.91, P=0.09, after transure-
thral microwave treatment; mean difference 3.90, 1.27
to 6.53, P=0.004, after transurethral needle ablation;
weighted mean difference 3.01, −1.06 to 7.07, P=0.15,
after laser coagulation.
Peak urine flow rate—The results for peak urine flow
rate at 12 months were generally consistent with those
for symptom scores (fig 1). Results of four trials that
presented data that could not be included in the meta-
analysis were consistent with these findings: weighted
mean difference −5.08, −8.32 to −1.83, P=0.002, after
transurethral microwave treatment; −9.04, −14.68 to
−3.40 , P=0.002, after transurethral needle ablation;
−5.50, −9.86 to −1.13, P=0.01, after laser coagulation.
Quality of life—Two,w5 w6 four,w7-w10 and sixw10 w12 w15
w16 w18 w20 studies comparing transurethral resectionwith
transurethral microwave treatment, transurethral nee-
dle ablation, and laser coagulation, respectively,
reported on quality of life using various instruments.
Scores after these interventions were generally poorer
than after transurethral resection, but we could not
undertake a formal meta-analysis (see table D on
bmj.com).
Blood transfusion—Blood transfusion was less com-
mon after minimally invasive treatments than after
transurethral resection (fig 2): relative risk 0.11, 95%
confidence interval 0.01 to 1.98, P=0.13, after transur-
ethral microwave treatment; 0.05, 0.01 to 0.32,
P=0.002, after transurethral needle ablation; 0.11, 0.04
to 0.26, P<0.001, after laser coagulation). No patients
undergoing transurethral microwave treatment or
transurethral needle ablation required a blood transfu-
sion.
Urinary retention—Laser coagulation was associated
with a higher rate of urinary retention than transurethral
resection (12.9% v 5.3%, relative risk 2.31, 1.11 to 4.80,
P=0.02). No significant differences were seen between
transurethral resection and transurethral microwave
treatment or transurethral needle ablation (fig 2).
Detailsof22includedstudies(22trialswith24relevantcomparisons)andsummaryofbaselinecharacteristics(meansormedians)
Study Comparators
No of
participants Age (years)
Symptom
score* Qmax ml/s
Residual
volume (ml)
Prostate size
(ml)
Ahmed 1997w1 TUMT v TURP 30/30 69/69 18.5/18.4 10.1/9.5 94/109 37/46
Dahlstrand 1993w2 TUMT v TURP 39/40 68/70 11.2†/13.3† 8.0/7.9 105/116 33/37
Dahlstrand 1995w3 TUMT v TURP 37/32 67/70 12.1†/13.6† 8.6/8.6 194/1104 43‡/45‡
D’Ancona 1998w4 TUMT v TURP 31/21 69/69 18.3/16.7 9.3/9.3 49/91 43/45
De la Rosette
2003w5
TUMT v TURP 78/66 67/66 20.0/20.0 9.2/8.0 65/91 51/52
Wagrell 2002w6 TUMT v TURP 99/46 67/69 21.0/20.4 7.6/7.8 106/94 49/53
Cimentepe 2003w7 TUNA v TURP 26/33 60/63 22.9/24.1 9.8/9.2 67/76 46/49
Hill 2004w8 TUNA v TURP 65/56 66/66 23.9/24.1 8.8/8.8 92/83 36/36
Hindley 2001w9 TUNA v TURP 25/25 66§/71§ 22§/20§ 8.5/9.0 55/74 NR/NR
Kim 2006w10 TUNA v TURP 110/110 66/67 20.8/24.0 7.0/11.9 257/187 41/44
Kim 2006w10 TEAP v TURP 94/110 66/67 19.5/24.0 7.2/11.9 126/187 36/44
Aliaga 1998w11 Laser coagulation v TURP 18/21 NR 25.5/24.2 7.0/8.3 77/89 20-60g/20-60g
Chacko
2001w12 (Clasp
study)
Laser coagulation v TURP 74/74 74/73 17.6/19.4 NR NR NR
Costello 1995w13 Laser coagulation v TURP 34/37 68/68 NR 8.76/9.48 NR 30/34
Cowles 1995w14 Laser coagulation v TURP 56/59 65/67 18.7/20.8 8.9/9.5 163/207 42/39
Donovan 2000w15
(Clasp study)
Laser coagulation v TURP 117/117 67/66 19.1/19.2 10.4/10.3 124/104 41/38
Gujral
2000w16 (Clasp
study)
Laser coagulation TURP 38/44 70/70 20.9/19.5 11.2/8.5 438/545 41§/50§
Kabalin 1995w17 Laser coagulation v TURP 13/12 65/69 20.9/18.8 8.5/9.0 236/291 24‡/17‡
Kim 2006w10 Laser coagulation v TURP 89/110 69/67 21.1/24.0 8.6/11.9 219/187 43/44
Kursh 2003w18 Laser coagulation v TURP 37/35 68/69 24.0§/23.0§ 9.2§/9.1§ 81§/87§ 41§/40§
Liedberg 2003w19 Laser coagulation TURP 20/11 NR/NR 19§/17§ 8§/8§ 96§/117§ 49§/47§
Mårtenson 1999w20 Laser coagulation v TURP 30/14 >45/>45 21.7/21.6 7.3/9.3 116/88 46/50
McAllister 2000w21 Laser coagulation v TURP 76/75 68/68 18.1/18.2 9.6/10.0 113/120.7 NR
Suvakovic 1996w22 Laser coagulation v TURP 10/10 67/66 15.7/18.8 10.5/11.1 47/162 24 g/22 g
NR=not reported; TUMT=transurethral microwave thermotherapy; TUNA=transurethral needle ablation; TEAP=transurethral ethanol ablation of prostate.
*International prostate symptom score/American Urological Association symptom index.
†Madsen score.
‡Prostate length (mm).
§Median.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 8
Strictures—Men undergoing a minimally invasive
treatment had a lower risk of developing strictures
(0.6% v 6.5%, relative risk 0.20, 0.05 to 0.75, P=0.02,
after transurethral microwave treatment; 0.5% v 6.8%,
0.14, 0.03 to 0.62, P=0.009, after transurethral needle
ablation; 0.9% v 8.6%, 0.18, 0.06 to 0.56, P=0.003, after
laser coagulation) (see fig B on bmj.com).
Incontinence—The risk of postoperative incontinence
was lower after transurethral needle ablation and laser
coagulation than after transurethral resection (0.9% v
8.0%, relative risk 0.16, 0.05 to 0.51, P=0.002; 0% v
3.9%, 0.16, 0.04 to 0.71, P=0.02, respectively), while
there was no significant difference after transurethral
microwave treatment (4.9% v 8.3%, 0.61, 0.30 to 1.26,
P=0.18) (see fig B on bmj.com).
Urinary tract infection—There was no significant
difference in rates of urinary tract infection after
transurethral microwave treatment and transurethral
needle ablation compared with transurethral resection
(6.7% v 7.5%; 1.05, 0.53 to 2.08, P=0.90, after
transurethral microwave treatment; 10.3% v 7.0%;
1.42, 0.69 to 2.91, P=0.34, after transurethral needle
ablation). The rate of postoperative urinary tract
infection, however, was higher in patients after laser
coagulation (14.8% v 6.9%; 1.84, 1.22 to 2.79, P=0.004)
(see fig B on bmj.com).
Sexual dysfunction—Men undergoing a minimally
invasive treatment were less likely to experience loss
of ejaculation comparedwith thosehaving transurethral
resection. Also, after transurethral needle ablation or
laser coagulation sexually activemenhad a lower risk of
experiencing erectile dysfunction, but the difference
between transurethral microwave treatment and trans-
urethral resection was not significant (fig 3).
Descriptors of care—Compared with transurethral
resection, transurethral needle ablation procedures
were longer and laser coagulation procedures shorter
(fig 4). We had insufficient data to assess differences in
duration of operationbetween transurethralmicrowave
treatment and transurethral resection.Hospital staywas
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Transurethral microwave treatment
  D’Ancona 1998w4
  Wagrell 2002w6
  De la Rosette 2003w5
Total (95% CI): 2.26 (-0.38 to 4.91), P=0.09, I2=84.1%
Transurethral needle ablation
  Hill 2004w8
Total (95% CI): 3.90 (1.27 to 6.53), P=0.004
Laser coagulation
  Kabalin 1995w17
  Martenson 1999w20
  McAllister 2000w21
  Suvakovic 1996w22
Total (95% CI): 3.01 (-1.06 to 7.07), P=0.15, I2=83.4%
Transurethral microwave treatment
  D’Ancona 1998w4
  Dahistrand 1995w3
  Wagrell 2002w6
  De la Rosette 2003w5
Total (95% CI): 5.08 (-8.32 to -1.83), P=0.002, I2=71.5%
Transurethral needle ablation
  Hill 2004w8
  Hindley 2001w9
Total (95% CI): -9.04 (-14.68 to -3.40), P=0.002, I2=71.5%
Laser coagulation
  Kabalin 1995w17
  Martenson 1999w20
  McAllister 2000w21
  Suvakovic 1996w22
Total (95% CI): -5.50 (-9.86 to -1.13), P=0.01, I2=76.1%
Symptom score
Peak urine flow (ml/sec)
Fig 1 | Symptom scores (international prostate symptom score or American Urological Association symptom index) and peak urine
flow rate at 12 months (TURP=transurethral resection of prostate)
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onaverageoneday shorter for laser coagulation than for
transurethral resection (95% confidence interval −1.68
to −0.98 days, P<0.001) (fig 5). This was consistent with
results from other trials with data unsuitable for meta-
analysis. Concerning transurethral needle ablation, two
studies favoured transurethral resection of the prostate
w7 w9 and one favoured transurethral needle ablation.w10
Patients undergoing transurethralmicrowave treatment
were generally treated as day cases and therefore
hospital stay was clearly longer for transurethral
resection. The need for reoperation was more common
after a minimally invasive procedure (10.2% v 4.8%,
2.01, 0.96 to 4.18, P=0.06, after transurethral micro-
wave treatment; 6.2% v 0.5%, 6.89, 1.58 to 29.95,
P=0.01, after transurethral needle ablation; 7.9% v2.0%,
3.21, 1.65 to 6.24, P<0.001, after laser coagulation)
(fig 6).
DISCUSSION
Principle findings
A single minimally invasive treatment of benign
prostatic enlargement with transurethral microwave
treatment, transurethral needle ablation, or laser
coagulation results in improvement of symptoms at
12months, but this ismarkedly inferior to that seen after
transurethral resection of the prostate and in some trials
is associated with significantly less improvement in
quality of life. In our systematic review this difference in
subjective treatment response was mirrored by the
much smaller increase in peak urinary flow rate after a
minimally invasive treatment, signifying reduced uro-
dynamic benefit. The risk profile of minimally invasive
interventions was generally superior to transurethral
resection,with fewer adverse events in termsof the need
for a blood transfusion, development of strictures, and
urinary incontinence, but the risk of reoperation within
the relatively short follow-up periods reported was
between two and seven times higher than for transur-
ethral resection. Overall, our findings do not support a
change in surgical treatment of benign prostatic
enlargement away from the current standard of
transurethral resection. On an individual basis, how-
ever, personal preference will influence choice of
procedure and some patients might trade-off the lower
efficacy and higher risk of reoperation for the decreased
morbidity seen with minimally invasive treatment
options.
Meaning of the study (possible mechanism and
implications for policy and practice)
Although improvements in symptoms after minimally
invasive treatments was inferior to transurethral resec-
tion of the prostate, it still represents a considerable
treatment effect given that a reduction of more than 3
points in the international prostate symptom score is of
noticeable benefit for men with benign prostatic
enlargement.5 It might be better to use these techniques
earlier in the treatment algorithm, possibly as alter-
natives to long term drug treatment with α adrenergic
blockers or 5-α reductase inhibitors. One randomised
controlled trial showed superior efficacy in terms of
symptom scores, peak urine flow rate, and quality of life
with single transurethral microwave treatment at six
months after treatment compared with terazocin, an α
adrenergic antagonist.6 The closer equivalence with
drug treatment is also indicated by the substantially
lower improvement in peak flow rate compared with
transurethral resection, which is likely to reflect the
smaller quantity of prostate tissue ablated.Thepotential
benefits of this treatment strategy, however, require
further evaluation given the greater risk of potentially
serious adverse events such as infection and urinary
retention and the need for more focused selection of
patients compared with drug treatment.
Minimally invasive treatments for benign prostatic
enlargement were originally conceived as an attempt to
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Transurethral microwave treatment
  Ahmed 1997w1
  D’Ancona 1998w4
  Dahistrand 1995w3
Total (95% CI): 0.11 (0.01 to 1.98), P=0.13
Transurethral needle ablation
  Cimentepe 2003w7
  Hindley 2001w9
  Kim 2006w10
Total (95% CI): 0.05 (0.01 to 0.32), P=0.002, I2=0%
Laser coagulation
  Aliaga 1998w11
  Chacko 2001w12
  Costello 1995w13
  Cowles 1995w14
  Donovan 2000w15
  Gujral 2000w16
  Kabalin 1995w17
  Kim 2006w10
  Kursh 2003w18
  Martenson 1999w20
  McAllister 2000w21
Total (95% CI): 0.11 (0.04 to 0.26), P<0.001, I2=0%
Transurethral microwave treatment
  Wagrell 2002w6
  De la Rosette 2003w5
Total (95% CI): 1.64 (0.77 to 3.50), P=0.20, I2=0%
Transurethral needle ablation
  Cimetepe 2003w7
  Hindley 2001w9
  Kim 2006w10
Total (95% CI): 1.48 (0.49 to 4.52), P=0.49, I2=0%
Laser coagulation
  Cowles 1995w14
  Kim 2006w10
  Suvakovic 1996w22
Total (95% CI): 2.31 (1.11 to 4.80), P=0.02, I2=44.3%
0.001 0.01 1 1000.1 10 1000
Blood transfusion
Urinary retention
Fig 2 | Blood transfusion and urinary retention after interventions (TURP=transurethral resectionof
prostate)
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offer equivalent efficacy to transurethral resection
without the burden and risk of operative morbidity.
They have tended to be introduced in a haphazard and
uncontrolled manner and have yet to find their place as
approved treatments in healthcare systems such as the
UKNHS. Themain attraction tomen considering such
alternative treatments is the lower risk of adverse effects
and shorter recovery time. Our meta-analysis showed
that transurethral microwave treatment and transure-
thral needle ablation are less likely to lead to major
blood loss, which is of undoubted benefit to men with
major comorbidities. There was also evidence of lower
risk of sexual side effects such as ejaculatorydisturbance
anderectile dysfunction,whichpresumably relate to the
smaller amount of tissue ablation and the lower
temperatures used. This result should be interpreted
with caution given the lack of data on sexual activity
before treatment, although in randomised controlled
trials the two groups should be balanced at baseline.
Avoidance of these adverse effects was balanced by
increases in others, particularly the need for continued
catheterisation and reoperation. Laser coagulation was
associated with a higher risk of urinary retention, which
might reflect prostatic oedema subsequent to tissue
necrosisw13 and thismight also explain the higher rate of
urinary tract infection after this procedure.7 The
durability of symptomatic benefit after minimally
invasive treatments was poor compared with transure-
thral resection,with rates of reoperationover 12months
of 11%, 8%, and 7% for laser coagulation, transurethral
microwave treatment, and transurethral needle abla-
tion, respectively, comparedwith an absolute rate of 3%
forpatients after transurethral resection.This represents
amajor disadvantage of these techniques, particularly if
the rate of treatment failure continues to increase with
longer follow-up, as suggested by several studies
reporting outcome at two and five years after transur-
ethral microwave treatment.w8 w9 w18 w20 w21 This finding
provides a further argument against these technologies
as alternatives to transurethral resection but might
favour their use as a preliminary treatment, with
transurethral resection used for treatment failures.
Trials of incorporating repeated treatments with mini-
mally invasive devices should perhaps be encouraged.
Transurethral microwave treatment, transurethral
needle ablation, and laser coagulation were associated
with shorterdurationof operation andhospital stay, and
transurethral microwave treatment can even be carried
out as a day procedure,whichmight be advantageous to
4/18
14/46
18/64
0/26
0/65
5/100
5/191
2/16
1/12
4/89
1/20
9/24
17/161
0/18
0/37
7/35
7/90
0/26
2/65
1/100
3/191
0/16
3/56
0/89
0/28
3/189
Favours
intervention
Favours
TURP
Relative risk
(fixed) (95% CI)
Intervention
12/19
32/42
44/61
16/33
23/56
39/101
78/190
8/11
9/10
39/101
3/11
15/24
74/157
4/19
0/32
9/53
13/104
4/33
12/56
13/101
29/190
0/11
2/59
13/101
3/12
18/183
TURP
Transurethral microwave treatment
  Ahmed 1997w1
  De la Rosette 2003w5
Total (95% CI): 0.39 (0.25 to 0.59), P<0.01, I2=0%
Transurethral needle ablation
  Cimentepe 2003w7
  Hill 2004w8
  Kim 2006w10
Total (95% CI): 0.08 (0.03 to 0.17), P<0.01, I2=22.7%
Laser coagulation
  Costello 1995w13
  Kabalin 1995w17
  Kim 2006w10
  Liedberg 2003w19
  McAllister 2000w21
Total (95% CI): 0.22 (0.14 to 0.35), P<0.01, I2=69.6%
Transurethral microwave treatment
  Ahmed 1997w1
  Dahistrand 1995w3
  De la Rosette 2003w5
Total (95% CI): 0.77 (0.35 to 1.73), P=0.53, I2=60.6%
Transurethral needle ablation
  Cimentepe 2003w7
  Hill 2004w8
  Kim 2006w10
Total (95% CI): 0.11 (0.04 to 0.34), P<0.01, I2=0%
Laser coagulation
  Costello 1995w13
  Cowles 1995w14
  Kim 2006w10
  Martenson 1999w20
Total (95% CI): 0.20 (0.07 to 0.58), P<0.01, I2=71.9%
0.001 0.01 1 1000.1 10 1000
Loss of ejaculation
Erectile dysfunction
Fig 3 | Sexual function after interventions (TURP=transurethral resection of prostate)
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patients, society, and healthcare providers.8 This,
together with the lower risk of serious complications,
suggests that minimally invasive treatments might offer
significant cost savings over transurethral resection, but
the importance of these savings would need to be set
against differences in effectiveness and subsequent
treatment costs such as need for reoperation and safety
within a formal economic evaluation. In addition, better
managed pathways and improved perioperative care
might mitigate against these perceived advantages of
minimally invasive treatments.
Strengths and limitations
We could not assess the clinical effectiveness of other
minimally invasive treatments—such as high intensity
focused ultrasound, water thermotherapy, and transur-
ethral ethanol ablation of prostate—because of the
limited data available. If these techniques seem to hold
promise, methodologically sound randomised con-
trolled trials comparing them with current practice
would be necessary.
Alsowe could not assess the extent of publication bias
as most of the available evidence (53 randomised
controlled trials) was excluded because it was reported
only in abstract form.Unpublished reports tend to show
less positive results9 and so the exclusion of these
abstracts might have introduced bias in favour of the
newer interventions. Although 22 trials were eligible,
most had suboptimal reporting or methods and
recruited small numbers of patients, with many failing
to report point estimates and measures of variability,
hindering the calculationof aweightedmeandifference.
If thesedetailsweremadeavailable, effect sizesmight be
different. This is another reason why adherence by
authors and journals to CONSORT guidelines would
greatly aid the conduct of robust meta-analyses.
Heterogeneity in results for the primary outcome
measure of reduction in symptom score presented
problems in deriving a valid meta-analysis, which we
overcame by using a random effects model. Clinical
reasons for this heterogeneity include differences in
baseline symptoms score between studies and failure to
control for other variables that might result in greater
symptomatic improvement, such as initial prostate
volume and the presence of urodynamic obstruction.
Other methodological limitations resulted from
variation in inclusion criteria, operative technique,
and treatment protocols between trials investigating
the same technology. Thiswas particularly true for laser
coagulation, forwhichmany trials failed to reportpower
settings, temperature, and site or duration of laser
application. Such limited descriptions of technologies
made it hard to determine whether they were truly
minimally invasive or involved some immediate tissue
removal. This is an important possible explanation for
the statisticalheterogeneity thatwas common to someof
the analyses.
Though our conclusions generally concur with the
other recently published reviews,1011 we found some
differences in effect estimates but the direction of effect
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Fig 6 | Number of patients who underwent reoperation (TURP=transurethral resection of prostate)
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is generally consistent. One exception was the study by
Bouza and colleagues that compared transurethral
needle ablation with transurethral resection of the
prostate.10 They reported a considerably higher risk of
urinary retention after transurethral resection and a
different direction of effect for urinary tract infections
favouring transurethral needle ablation. These marked
differences might be caused by different objectives and
inclusion criteria between reviews and because Bouza
and colleagues combined results from non-randomised
and randomised studies to provide a single pooled
estimate in the study. This type of analysis can generate
biased estimates of the treatment effect and might
decrease precision.9
Conclusion
We used the best available techniques to identify,
review, andmeta-analyse available data concerning the
therapeutic effect of minimally invasive surgical treat-
ments for benign prostatic enlargement compared with
transurethral resection of the prostate. Our results
suggest these treatments should be used earlier in the
care pathway and therefore further studies to determine
advantage over drug treatment or policies that include
the option of sequential treatments are needed. For the
NHS, the use of these minimally invasive options is not
otherwise appropriate and transurethral resection of the
prostate or other endoscopic techniques that result in
immediate tissue removal should be preferred.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Transurethral resection of the prostate is the current standard surgical procedure formenwith
clinically benign prostatic enlargement
It provides a consistent high likelihood of improvement, which persists in the long term but is
associated with relatively high risk of adverse events
Minimally invasive treatments have been tried in clinical practice
WHAT THIS STUDY ADDS?
Minimally invasive treatments result in poorer improvement in symptoms and urodynamic
parameters than transurethral resection but cause fewer adverse events
Rates of reoperation are higher after a minimally invasive treatment than after transurethral
resection
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